D027 CCM1 CPE Activity: Phases 1-3 Synthesis & Feedback Summaries
Student Name
Western Governors University
D027 Advanced Pathopharmacological Foundations
Prof. Name
Date
D027 CCM1 CPE Activity: Phases 1-3 Synthesis & Feedback Summaries
Phase 1: Timeline and Estimated Completion
The initial phase of the CPE activity outlines specific tasks, proposed completion dates, and the estimated time required for each assignment. The focus is on organizing and synthesizing clinical content efficiently.
| Task Description | Proposed Completion Date | Estimated Time to Complete |
|---|---|---|
| 1a. Create CPE schedule table | June 10, 2024 | 30 minutes |
| 1b. Develop Feedback and Synthesis Improvement Plan | June 25, 2024 | 2 hours |
| 1b. Pathophysiology Synthesis | June 25, 2024 | 2 hours |
| 1c. Capture Three GoReact Screenshots and Reflection | June 25, 2024 | 1.5 hours |
Phase 2: Timeline and Estimated Completion
In phase two, the focus shifts to reviewing progress and refining patient-centered synthesis materials. Similar to Phase 1, deadlines and time allocations are clearly defined.
| Task Description | Proposed Completion Date | Estimated Time to Complete |
|---|---|---|
| 2a. Review progress of CPE schedule table | June 30, 2024 | 30 minutes |
| 2b. Update Feedback and Synthesis Improvement Plan | June 30, 2024 | 2 hours |
| 2b. Patient or Healthcare Consumer-Focused Synthesis | June 30, 2024 | 2 hours |
| 2c. Capture Three GoReact Screenshots and Reflection | June 30, 2024 | 1.5 hours |
Phase 3: Timeline and Estimated Completion
The third phase involves further review, synthesis development targeted at professional colleagues, and treatment planning. The time allocations for tasks reflect increasing complexity.
| Task Description | Proposed Completion Date | Estimated Time to Complete |
|---|---|---|
| 3a. Review progress of CPE schedule table | July 4, 2024 | 30 minutes |
| 3b. Update Feedback and Synthesis Improvement Plan | July 4, 2024 | 2 hours |
| 3b. Preceptor or Colleague-Focused Synthesis | July 4, 2024 | 2 hours |
| 3c. Further Feedback and Synthesis Improvement Plan | July 4, 2024 | 2 hours |
| 3c. Patient or Healthcare Consumer-Focused Treatment Plan | July 4, 2024 | 2 hours |
| 3d. Capture Three GoReact Screenshots and Reflection | July 4, 2024 | 2 hours |
Phase 1.1B: Advanced Professional Nurse or Colleague Pathophysiology Synthesis
What Constitutes Chronic Lower Respiratory Infection, and What Are Its Pathophysiological Mechanisms?
Chronic lower respiratory infections are a group of persistent pulmonary diseases characterized by ongoing inflammation and structural deterioration of the lower airways. These diseases result in lasting respiratory symptoms and impaired lung function (World Health Organization [WHO], 2017). The specific pathophysiological processes vary according to the condition:
Chronic Obstructive Pulmonary Disease (COPD): This condition mainly stems from long-term exposure to harmful substances such as tobacco smoke, triggering chronic airway inflammation, bronchitis, and destruction of alveoli (emphysema).
Bronchiectasis: Marked by irreversible dilation and damage of the bronchi caused by recurrent infections, bronchiectasis impairs normal mucus clearance.
Chronic Pneumonia: Characterized by persistent infection and inflammation from diverse pathogens, chronic pneumonia leads to continual lung tissue injury (Wheeldon, 2023).
What Clinical Signs and Diagnostic Methods Are Common?
Patients suffering from chronic lower respiratory infections frequently present with the following symptoms:
Persistent cough producing sputum
Wheezing and difficulty breathing
Repeated respiratory infections
In advanced cases, symptoms like weight loss, fatigue, and respiratory failure (Mandell & Read, 2010)
Diagnosis is multifaceted, incorporating:
Detailed clinical history and physical examination
Pulmonary function tests such as spirometry
Imaging techniques including chest X-rays and CT scans
Microbiological evaluation of sputum to detect causative organisms (Mahashur, 2018)
How Are Chronic Lower Respiratory Infections Managed?
The therapeutic goal is to relieve symptoms, slow disease progression, and enhance lung function. Treatment varies by disease type:
| Condition | Treatment Modalities | Purpose |
|---|---|---|
| COPD | Smoking cessation, inhaled bronchodilators, corticosteroids, pulmonary rehab, vaccinations | Reduce inflammation and improve airflow |
| Bronchiectasis | Airway clearance, targeted antibiotics, immunizations | Manage infections and maintain airway patency |
| Chronic Pneumonia | Antibiotic therapy tailored to pathogens, supportive care, vaccinations | Eliminate infection and prevent recurrence |
What Feedback Was Received on the Synthesis?
Healthcare professionals reviewed the pathophysiology synthesis positively, commending its clarity, comprehensive coverage of etiology, clinical features, diagnostics, and treatment. No specific recommendations for improvement were given, indicating the synthesis met educational objectives effectively. Reviewers demonstrated strong understanding by summarizing disease characteristics accurately, reinforcing the synthesis’s quality.
Phase 1C: GoReact Video Reflection Summary
The synthesis on chronic lower respiratory infections aimed to provide healthcare providers with a concise yet comprehensive educational resource. Drawing from practical nursing experience and credible academic sources, the content was meticulously researched.
The main challenge was to distill extensive clinical information into a single-page format without sacrificing important details. Peer feedback was overwhelmingly positive, emphasizing the organized structure and clarity, which facilitated understanding of complex concepts. However, given reviewers’ familiarity with the subject, the scope for suggestions was limited. Their ability to articulate key points clearly reflected a solid grasp of the content.
Phase 2.2B: Patient or Healthcare Consumer-Focused Synthesis
What Is a Stroke and What Are Its Types?
A stroke, also known as a cerebrovascular accident (CVA), occurs when blood flow to a portion of the brain is interrupted due to either a blockage (ischemic stroke) or a ruptured blood vessel (hemorrhagic stroke). This disruption deprives brain cells of oxygen, leading to cell death (American Heart Association, 2021).
What Symptoms Are Typical?
Stroke symptoms depend on the affected brain region but typically include:
Sudden weakness or numbness, usually on one side of the body
Speech difficulties or trouble understanding language
Severe headache
Loss of balance or coordination
Visual impairments
The acronym F-A-S-T—Facial drooping, Arm weakness, Speech difficulties, and Time to call emergency services—is an essential tool for early recognition (National Institute of Neurological Disorders and Stroke [NINDS], n.d.).
How Is Stroke Diagnosed?
Diagnosis includes:
Clinical evaluation and detailed patient history
Imaging such as CT or MRI scans to identify stroke type and location
Blood tests to assess risk factors and potential causes (American Heart Association, 2021)
What Are the Treatment Options?
Stroke treatment aims to restore blood flow rapidly and minimize brain damage:
Ischemic Stroke: Use of thrombolytics like tissue plasminogen activator (tPA) or mechanical clot removal
Hemorrhagic Stroke: Management of bleeding, reduction of intracranial pressure, and sometimes surgical intervention
Post-stroke rehabilitation involves physical, occupational, and speech therapy for recovery
What Preventative Strategies Are Advised?
Preventing stroke focuses on risk factor management, including blood pressure control, healthy diet, smoking cessation, and regular physical activity (NINDS, n.d.).
What Feedback Did Healthcare Consumers Offer?
Healthcare consumers reported the stroke synthesis to be clear and useful, especially for recognizing symptoms and knowing when to seek emergency help. They recommended highlighting key terms to improve retention. Their ability to restate the information indicated the material effectively enhanced health literacy.
Phase 2C: GoReact Video Reflection Summary
This stroke synthesis was specifically designed for healthcare consumers, with an emphasis on simplifying medical jargon. The challenge lay in balancing conciseness with accessibility for non-medical readers.
Feedback was favorable, praising the clarity and succinctness of the content. The suggestion to emphasize key terms was noted to enhance engagement and comprehension. This experience underscored the significance of tailoring health education to the audience’s literacy level to maximize impact.
Phase 3: 3B Advanced Professional Nurse or Colleague Synthesis and Patient Treatment Plan
Case Summary: Ms. O’Connor’s COPD
Ms. O’Connor, a 55-year-old woman, has worsening COPD symptoms including productive cough and bronchospasm. Despite nicotine replacement therapy, she continues smoking 3-5 cigarettes daily. Spirometry reveals a forced expiratory volume in 1 second (FEV1) of 1.37 liters, representing 49% of predicted lung function. Her family history includes smoking-related illnesses, and she has gained weight over two years.
What Is the Pathophysiology of COPD?
COPD is a chronic inflammatory lung disease caused by inhaling harmful particles, leading to airway narrowing, loss of lung elasticity, and air trapping (Agarwal et al., 2023). These changes cause symptoms like cough, shortness of breath, and sputum production.
What Are Common Signs and Symptoms?
Typical clinical features include:
Shortness of breath (dyspnea)
Chronic cough and wheezing
Excess mucus production
Reduced exercise tolerance
Physical signs such as barrel chest, cyanosis, and clubbing of fingers (Agarwal et al., 2023)
How Is COPD Diagnosed?
Diagnosis is confirmed by:
Clinical history and symptom assessment
Pulmonary function tests (spirometry)
Imaging studies (chest X-ray, CT scan)
Arterial blood gas analysis
Screening for alpha-1 antitrypsin deficiency (Agarwal et al., 2023)
What Treatment Options Are Available, and What Are Potential Side Effects?
| Treatment Type | Medication Examples | Purpose | Possible Side Effects |
|---|---|---|---|
| Bronchodilators | Short-acting: Albuterol | Relax airways | Tremors, tachycardia, headaches |
| Long-acting: Tiotropium | Maintain airway openness | Dry mouth, cough | |
| Inhaled Corticosteroids | Formoterol | Reduce airway inflammation | Oral thrush, hoarseness (use mouthwash) |
| Smoking Cessation | Bupropion | Aid smoking cessation | Insomnia, dry mouth, tremors, seizure risk |
Non-pharmacological interventions like pulmonary rehabilitation and immunizations also play essential roles in COPD management (Agarwal et al., 2023).
What Feedback Was Provided on the COPD Synthesis and Treatment Plan?
Colleagues commended the synthesis for its clear, thorough, and accessible presentation. The use of bolded key terms improved information retention. Interaction with Shadow Health simulations enhanced clinical knowledge, assessment skills, and confidence in COPD management. The experience highlighted the critical role of effective patient education in improving health outcomes.
References
Agarwal, A. K., Raja, A., & Brown, B. D. (2023, August 7). Chronic obstructive pulmonary disease. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK559281/
American Heart Association. (2021). About stroke. American Stroke Association. https://www.stroke.org/en/about-stroke
Mahashur, A. (2018). Management of lower respiratory tract infection in outpatient settings: Focus on clarithromycin. Lung India, 35(2), 143–149. https://doi.org/10.4103/lungindia.lungindia_262_17
Mandell, L. A., & Read, R. C. (2010). Infections of the lower respiratory tract. In Antibiotic and Chemotherapy (pp. 574–588). https://doi.org/10.1016/B978-0-7020-4064-1.00045-2
National Heart Lung and Blood Institute. (2023). Treatment. https://www.nhlbi.nih.gov/health/copd/treatment
National Institute of Neurological Disorders and Stroke. (n.d.). Signs and symptoms. https://www.ninds.nih.gov/health-information/stroke/signs-and-symptoms
National Institute of Neurological Disorders and Stroke. (n.d.). Assess and treat. https://www.ninds.nih.gov/health-information/stroke/assess-and-treat
National Institute of Neurological Disorders and Stroke. (n.d.). Prevention. https://www.ninds.nih.gov/health-information/stroke/prevention
U.S. National Library of Medicine. (n.d.). Albuterol oral inhalation: Medlineplus Drug Information. https://medlineplus.gov/druginfo/meds/a682145.html
U.S. National Library of Medicine. (n.d.). Tiotropium oral inhalation: Medlineplus Drug Information. https://medlineplus.gov/druginfo/meds/a604018.html
D027 CCM1 CPE Activity: Phases 1-3 Synthesis & Feedback Summaries
U.S. National Library of Medicine. (n.d.-c). Formoterol oral inhalation: Medlineplus Drug Information. https://medlineplus.gov/druginfo/meds/a602023.html
U.S. National Library of Medicine. (n.d.). Bupropion: Medlineplus Drug Information. https://medlineplus.gov/druginfo/meds/a695033.html
Wheeldon, A. (2023). The respiratory system and associated disorders. British Journal of Nursing, 32(13), 613–619. https://doi.org/10.12968/bjon.2023.32.13.613
World Health Organization (WHO). (2017). Chronic obstructive pulmonary disease (COPD). https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)
Get WGU Free MSN Samples
D024
- D024 SEI Skill Sets Discussion – Self-Awareness & Management Insights
- D024 Phase 1 Video Reflection
- D024 CPE Schedule and SEI Reflection Report
- D024 FAQ: Submission and CPE Record Guidance
- D024 Phase 1 Reflection on Leadership and Growth Strategies
- D024 Joy in the Workplace: Force Field Analysis Summary
- D024 Professional Presence & Influence: CPE Record Template Task 1
D025
- D025 Phase 2 Reflection: Insights on Team Leadership and Advocacy
- D025: Phase 1 Reflection on Health Policy Advocacy Insights
- D025 Task 1: Clinical Practice Experience
- D025 Task 1 ISBAR Summary
- D025 Final Exam: Advocacy for Policy Change in Community Health
- D025 Task 2 Advocating for Policy Change to Improve Health Outcomes in the Community
D026
D027
- D027 Alzheimer’s Disease (AD) Final Synthesis: Understanding Key Aspects
- D027 OA Final Exam Study Guide: Key Concepts and Conditions
- D027 Shadow Health Treatment Plan for Dr. Douglas: Phase 3 Guide
- D027 CCM1 CPE Activity: Phases 1-3 Synthesis & Feedback Summaries
- D027 – Comprehensive Study Guide for Health Disorders and Treatments
- D027 E-Portfolio: Advanced Pathopharmacological Foundations
- D027 Study Guide – Advanced Pathopharmacology Notes
D028
D029
- D029 Narrative Essay: Innovations in Nursing Informatics
- D029 CPE Phase 2
- D029 Emerging Tech Annotated Bibliography for Nursing Care
- D029 Annotated Bibliography
- D029 Population Health Data Paper
- D029 Task 1 E-Portfolio: Clinical Practice Experience Analysis
- D029 Task 1: Analyzing Population Health Data in Strafford Country
D030
D031